<p>Sensus Healthcare（納斯達克代碼：SRTS - 獲取免費報告）於週四發佈了季度財報。該公司報告本季度每股收益為（$0.16），低於市場共識預期的（$0.12）$0.04，Zacks 報道。該公司本季度的收入為 339 萬美元，而分析師預期為 532 萬美元。Sensus Healthcare 的股本回報率為負 15.11%，淨利潤率為負 28.09%。</p>
<p>獲取 <strong>Sensus Healthcare</strong> 的提醒：</p>
<p>以下是 Sensus Healthcare 電話會議的關鍵要點：</p>
<ul>
<li>Sensus 表示，2026 年 1 月 1 日起生效的新專用 <strong>CPT 代碼</strong> 實質性改善了報銷——包括每次治療代碼約 <strong>300% 的增加</strong>——早期的 EOB 顯示付款方正在處理索賠，管理層表示這推動了醫生的更強興趣和管道增長。</li>
<li>第一季度收入為 340 萬美元，而去年同期為 830 萬美元，主要是因為沒有對公司歷史上最大的客户進行銷售；調整後的 EBITDA 為負 <strong>420 萬美元</strong>，淨虧損為 <strong>260 萬美元</strong>，儘管管理層指出在排除該客户後仍有基礎增長。</li>
<li>管理層優先考慮通過 <strong>Sensus Link</strong> 軟件和公平交易/租賃計劃（18 個活躍的公平交易地點，9 個待定）來實現經常性收入，並強調了一個可報銷的每週放射物理代碼（約$93.85/周），可以通過 Sensus Link 進行貨幣化並與客户分享。</li>
<li>商業擴展計劃——第一季度發貨 14 個系統（10 個直接，4 個公平交易/租賃），約 <strong>70% 的系統購買</strong> 發生在本季度，推出 <strong>Sensus Healthcare Financial Services</strong>，以及更強的會議驅動管道——支撐了管理層對第二季度/下半年收入增長和全年盈利能力的預期。</li>
</ul>
<h2>Sensus Healthcare 股票下跌 25.1%</h2>
<p>週五午盤交易中，SRTS 股票下跌$1.03，達到$3.08。該公司的股票交易量為 665,134 股，而其平均交易量為 84,977 股。Sensus Healthcare 的 52 周低點為$2.82，52 周高點為$5.92。該股票的市值為 5070 萬美元，市盈率為-6.55，貝塔值為 1.19。該公司的 50 日簡單移動平均為$4.14，200 日簡單移動平均為$4.16。</p>
<h2>分析師評級變動</h2>
<p>幾位分析師最近對該股票發表了看法。華爾街 Zen 在 2 月 14 日的報告中將 Sensus Healthcare 的股票評級從 “持有” 下調至 “賣出”。Maxim Group 在 2 月 17 日的研究報告中將 Sensus Healthcare 的目標價從$8.00 下調至$6.00，並對該股票給予 “買入” 評級。花旗集團在週五的研究報告中重新發布了對 Sensus Healthcare 的 “買入” 評級。Alliance Global Partners 在 3 月 6 日的研究報告中開始覆蓋 Sensus Healthcare 的股票。他們對該股票設定了 “買入” 評級和$7.50 的目標價。最後，Weiss Ratings 在 4 月 21 日的研究報告中重新發布了對 Sensus Healthcare 的 “賣出（d）” 評級。五位投資分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat，該公司目前的共識評級為 “適度買入”，平均目標價為$6.88。</p>
<p><strong>查看我們關於 Sensus Healthcare 的最新研究報告</strong></p>
<h2>對 Sensus Healthcare 的對沖基金看法</h2>
<p>一些對沖基金和其他機構投資者最近買入和賣出了 SRTS 的股票。Geode Capital Management LLC 在第二季度將其在 Sensus Healthcare 的持股增加了 2.5%。Geode Capital Management LLC 目前擁有 153,917 股該公司的股票，價值 73 萬美元，在上個季度購買了額外的 3,766 股。Jane Street Group LLC 在第四季度購買了 Sensus Healthcare 的新頭寸，價值 79,000 美元。State Street Corp 在第四季度將其在 Sensus Healthcare 的持股增加了 5.2%。State Street Corp 目前擁有 69,252 股該公司的股票，價值 27.6 萬美元，在上個季度購買了額外的 3,400 股。Ingalls &amp; Snyder LLC 在第四季度購買了 Sensus Healthcare 的新頭寸，價值 21.9 萬美元。最後，Greenline Wealth Management LLC 在第四季度購買了 Sensus Healthcare 的新頭寸，價值 51.3 萬美元。25.30% 的股票由機構投資者持有。</p>
<h2>關於 Sensus Healthcare</h2>
<p>（獲取免費報告）</p>
<p>Sensus Healthcare, Inc 是一家醫療技術公司，專注於開發、製造和商業化表面放射治療（SRT）系統。該公司的 SRT 設備利用低能 X 射線治療多種皮膚病和腫瘤疾病，尤其是非黑色素瘤皮膚癌，如基底細胞癌和鱗狀細胞癌，以及包括瘢痕疙瘩在內的良性病變。通過向表層組織層提供靶向輻射，Sensus Healthcare 的系統旨在為合格患者提供一種替代外科切除或系統治療的非侵入性治療選擇。</p>
<p>該公司的旗艦產品包括 SRT-100™和 SRT-100+™平台，具有手持式應用器、可調能量設置和集成安全控制。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Sensus Healthcare</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JUUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JUUw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Sensus Healthcare 嗎？</h2>
<p>在你考慮 Sensus Healthcare 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Sensus Healthcare 並不在名單上。</p>
<p>雖然 Sensus Healthcare 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Sensus醫療保健

美國醫藥設備 ETF - iShares

標普健康醫療設備 ETF - SPDR

<p>Sensus Healthcare（納斯達克代碼：SRTS）報告的季度收益為每股虧損 0.16 美元，低於預期 0.04 美元。收入為 339 萬美元，低於預期的 532 萬美元。該公司的淨利潤率為負 28.09%，股本回報率為負 15.11%。儘管結果令人失望，管理層預計由於新的報銷代碼和商業擴展計劃，第二季度/下半年的收入將會增加。股價下跌 25.1%，至 3.08 美元，分析師將其評級為 “適度買入”，共識目標價為 6.88 美元</p>

<p>Sensus Healthcare (NASDAQ:SRTS - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.04), Zacks reports. The firm had revenue of $3.39 million for the quarter, compared to analyst estimates of $5.32 million. Sensus Healthcare had a negative return on equity of 15.11% and a negative net margin of 28.09%.</p>
<div class="lb-trans"><p>Sensus Healthcare（納斯達克代碼：SRTS - 獲取免費報告）於週四發佈了季度財報。該公司報告本季度每股收益為（$0.16），低於市場共識預期的（$0.12）$0.04，Zacks 報道。該公司本季度的收入為 339 萬美元，而分析師預期為 532 萬美元。Sensus Healthcare 的股本回報率為負 15.11%，淨利潤率為負 28.09%。</p>
</div><p>Get <strong>Sensus Healthcare</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Sensus Healthcare</strong> 的提醒：</p>
</div><p>Here are the key takeaways from Sensus Healthcare's conference call:</p>
<div class="lb-trans"><p>以下是 Sensus Healthcare 電話會議的關鍵要點：</p>
</div><ul>
<li>Sensus says new dedicated <strong>CPT codes</strong> effective Jan 1, 2026 materially improve reimbursement — including about a <strong>300% increase</strong> in the per‑fraction delivery code — and early EOBs show payers are processing claims, which management says is driving stronger physician interest and pipeline growth.</li>
<li>Q1 revenue was $3.4 million versus $8.3 million a year ago primarily because there were no sales to the company's historically largest customer; adjusted EBITDA was negative <strong>$4.2 million</strong> and net loss was <strong>$2.6 million</strong>, though management notes underlying growth when excluding that customer.</li>
<li>Management is prioritizing recurring revenue through the <strong>Sensus Link</strong> software and the Fair Deal/rental program (18 active Fair Deal sites, 9 pending), and highlighted a reimbursable weekly radiation physics code (~$93.85/week) that can be monetized and shared with customers via Sensus Link.</li>
<li>Commercial expansion initiatives — 14 systems shipped in Q1 (10 direct, 4 Fair Deal/rental), ~ <strong>70% purchases</strong> of systems in the quarter, the launch of <strong>Sensus Healthcare Financial Services</strong>, and a stronger conference-driven pipeline — underpin management's expectation of higher Q2/H2 revenue and a path to full‑year profitability.</li>
</ul>
<div class="lb-trans"><ul>
<li>Sensus 表示，2026 年 1 月 1 日起生效的新專用 <strong>CPT 代碼</strong> 實質性改善了報銷——包括每次治療代碼約 <strong>300% 的增加</strong>——早期的 EOB 顯示付款方正在處理索賠，管理層表示這推動了醫生的更強興趣和管道增長。</li>
<li>第一季度收入為 340 萬美元，而去年同期為 830 萬美元，主要是因為沒有對公司歷史上最大的客户進行銷售；調整後的 EBITDA 為負 <strong>420 萬美元</strong>，淨虧損為 <strong>260 萬美元</strong>，儘管管理層指出在排除該客户後仍有基礎增長。</li>
<li>管理層優先考慮通過 <strong>Sensus Link</strong> 軟件和公平交易/租賃計劃（18 個活躍的公平交易地點，9 個待定）來實現經常性收入，並強調了一個可報銷的每週放射物理代碼（約$93.85/周），可以通過 Sensus Link 進行貨幣化並與客户分享。</li>
<li>商業擴展計劃——第一季度發貨 14 個系統（10 個直接，4 個公平交易/租賃），約 <strong>70% 的系統購買</strong> 發生在本季度，推出 <strong>Sensus Healthcare Financial Services</strong>，以及更強的會議驅動管道——支撐了管理層對第二季度/下半年收入增長和全年盈利能力的預期。</li>
</ul>
</div><h2>Sensus Healthcare Stock Down 25.1%</h2>
<div class="lb-trans"><h2>Sensus Healthcare 股票下跌 25.1%</h2>
</div><p>SRTS stock traded down $1.03 during midday trading on Friday, reaching $3.08. The company's stock had a trading volume of 665,134 shares, compared to its average volume of 84,977. Sensus Healthcare has a 52 week low of $2.82 and a 52 week high of $5.92. The stock has a market cap of $50.70 million, a PE ratio of -6.55 and a beta of 1.19. The business's 50-day simple moving average is $4.14 and its 200-day simple moving average is $4.16.</p>
<div class="lb-trans"><p>週五午盤交易中，SRTS 股票下跌$1.03，達到$3.08。該公司的股票交易量為 665,134 股，而其平均交易量為 84,977 股。Sensus Healthcare 的 52 周低點為$2.82，52 周高點為$5.92。該股票的市值為 5070 萬美元，市盈率為-6.55，貝塔值為 1.19。該公司的 50 日簡單移動平均為$4.14，200 日簡單移動平均為$4.16。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>Several analysts have recently weighed in on the stock. Wall Street Zen lowered shares of Sensus Healthcare from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, February 14th. Maxim Group decreased their price target on shares of Sensus Healthcare from $8.00 to $6.00 and set a &#34;buy&#34; rating on the stock in a research note on Tuesday, February 17th. Citigroup reissued a &#34;buy&#34; rating on shares of Sensus Healthcare in a research note on Friday. Alliance Global Partners assumed coverage on shares of Sensus Healthcare in a research note on Friday, March 6th. They set a &#34;buy&#34; rating and a $7.50 price target on the stock. Finally, Weiss Ratings reissued a &#34;sell (d)&#34; rating on shares of Sensus Healthcare in a research note on Tuesday, April 21st. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $6.88.</p>
<div class="lb-trans"><p>幾位分析師最近對該股票發表了看法。華爾街 Zen 在 2 月 14 日的報告中將 Sensus Healthcare 的股票評級從 “持有” 下調至 “賣出”。Maxim Group 在 2 月 17 日的研究報告中將 Sensus Healthcare 的目標價從$8.00 下調至$6.00，並對該股票給予 “買入” 評級。花旗集團在週五的研究報告中重新發布了對 Sensus Healthcare 的 “買入” 評級。Alliance Global Partners 在 3 月 6 日的研究報告中開始覆蓋 Sensus Healthcare 的股票。他們對該股票設定了 “買入” 評級和$7.50 的目標價。最後，Weiss Ratings 在 4 月 21 日的研究報告中重新發布了對 Sensus Healthcare 的 “賣出（d）” 評級。五位投資分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat，該公司目前的共識評級為 “適度買入”，平均目標價為$6.88。</p>
</div><p><strong>Check Out Our Latest Research Report on Sensus Healthcare</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Sensus Healthcare 的最新研究報告</strong></p>
</div><h2>Hedge Funds Weigh In On Sensus Healthcare</h2>
<div class="lb-trans"><h2>對 Sensus Healthcare 的對沖基金看法</h2>
</div><p>A number of hedge funds and other institutional investors have recently bought and sold shares of SRTS. Geode Capital Management LLC boosted its position in shares of Sensus Healthcare by 2.5% during the second quarter. Geode Capital Management LLC now owns 153,917 shares of the company's stock worth $730,000 after purchasing an additional 3,766 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Sensus Healthcare during the fourth quarter worth $79,000. State Street Corp boosted its position in shares of Sensus Healthcare by 5.2% during the fourth quarter. State Street Corp now owns 69,252 shares of the company's stock worth $276,000 after purchasing an additional 3,400 shares in the last quarter. Ingalls &amp; Snyder LLC bought a new position in shares of Sensus Healthcare during the fourth quarter worth $219,000. Finally, Greenline Wealth Management LLC bought a new position in shares of Sensus Healthcare during the fourth quarter worth $513,000. 25.30% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近買入和賣出了 SRTS 的股票。Geode Capital Management LLC 在第二季度將其在 Sensus Healthcare 的持股增加了 2.5%。Geode Capital Management LLC 目前擁有 153,917 股該公司的股票，價值 73 萬美元，在上個季度購買了額外的 3,766 股。Jane Street Group LLC 在第四季度購買了 Sensus Healthcare 的新頭寸，價值 79,000 美元。State Street Corp 在第四季度將其在 Sensus Healthcare 的持股增加了 5.2%。State Street Corp 目前擁有 69,252 股該公司的股票，價值 27.6 萬美元，在上個季度購買了額外的 3,400 股。Ingalls &amp; Snyder LLC 在第四季度購買了 Sensus Healthcare 的新頭寸，價值 21.9 萬美元。最後，Greenline Wealth Management LLC 在第四季度購買了 Sensus Healthcare 的新頭寸，價值 51.3 萬美元。25.30% 的股票由機構投資者持有。</p>
</div><h2>About Sensus Healthcare</h2>
<div class="lb-trans"><h2>關於 Sensus Healthcare</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company's SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare's systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.</p>
<div class="lb-trans"><p>Sensus Healthcare, Inc 是一家醫療技術公司，專注於開發、製造和商業化表面放射治療（SRT）系統。該公司的 SRT 設備利用低能 X 射線治療多種皮膚病和腫瘤疾病，尤其是非黑色素瘤皮膚癌，如基底細胞癌和鱗狀細胞癌，以及包括瘢痕疙瘩在內的良性病變。通過向表層組織層提供靶向輻射，Sensus Healthcare 的系統旨在為合格患者提供一種替代外科切除或系統治療的非侵入性治療選擇。</p>
</div><p>The company's flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.</p>
<div class="lb-trans"><p>該公司的旗艦產品包括 SRT-100™和 SRT-100+™平台，具有手持式應用器、可調能量設置和集成安全控制。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Sensus Healthcare</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Sensus Healthcare</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JUUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=SRTS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Sensus Healthcare Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Sensus Healthcare 嗎？</h2>
</div><p>Before you consider Sensus Healthcare, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Sensus Healthcare 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sensus Healthcare wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Sensus Healthcare 並不在名單上。</p>
</div><p>While Sensus Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Sensus Healthcare 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Sensus Healthcare (NASDAQ:SRTS) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Sensus 醫療保健（NASDAQ:SRTS）公佈季度財報，每股收益比預期低 0.04 美元